SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chee, K. H
Right arrow Articles by Lang, C. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chee, K. H
Right arrow Articles by Lang, C. C
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure

Kok H Chee

Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Kadirvelu Amudha

Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Nik A Hussain

Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Haron K Haizal

Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Anna-Maria J Choy

Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Chim C Lang

Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia, chimlang{at}um.edu.my

Conventional diuretic agents are very effective agents in relieving volume overload and congestive symptoms in chronic heart failure (CHF). However, they are associated with activation of the renin-angiotensin system (RAS) and the sympathetic nervous system and a reduction in glomerular filtration rate, all of which have been associated with adverse outcomes in CHF. Therefore, there is an increasing interest in drugs that target the natriuretic system without neurohormonal activation and deterioration of renal function. In this review, we will discuss the underlying rationale and evidence behind currently pursued strategies that target the natriuretic system. This includes the administration of natriuretic peptides (NPs) and strategies that potentiate the NP system, such as neutral endopeptidase inhibition. We will also highlight some potentially important interactions of these strategies with drugs that target the RAS.

Key Words: natriuretic peptides • ACE inhibitors • heart failure

References

  • Mann DL Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.[Free Full Text]
  • Costello-Boerrighter LC, Boerrigter G., Burnett JC Jr. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin N Am 2003;87:475-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Francis GS, Benedict C., Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub-study of the studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.[Abstract/Free Full Text]
  • Dries DL, Exner DV, Domanski MJ, Greenberg B., Stevenson LW The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.[Abstract/Free Full Text]
  • Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC, Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988;62:191-5.[Abstract/Free Full Text]
  • Kim JK, Summer SN, Durr J., Schrier RW Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. Kidney Int 1989;35:799-805.[Web of Science][Medline] [Order article via Infotrieve]
  • Mendez RE, Dunn BR,Troy JL, Brenner BM Modulation of the natriuretic response to atrial natriuretic peptide by alterations in peritubular Starling forces in the rat. Circ Res 1986; 59:605-11.[Abstract/Free Full Text]
  • Abraham WT, Hensen J., Kim JK et al. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol 1992; 2:1697-703.[Abstract]
  • Wu CF,* Bishopric NH, Pratt RE Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 1997;272:14860-6.[Abstract/Free Full Text]
  • Cao L., Gardner DG Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995;25:227-34.[Abstract/Free Full Text]
  • Cody RJ,Atlas SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-74.[Web of Science][Medline] [Order article via Infotrieve]
  • Lang CC, Prasad N., McAlpine HM et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J 1994;127:1635-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Choy AM, Darbar D., Lang CC et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994;72:16-22.[Abstract/Free Full Text]
  • Darbar D., Davidson NC, Gillespie N. et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 1996;78:284-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Latini R., Masson S., Anand I. et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8.[Abstract/Free Full Text]
  • Berger R., Huelsman M., Strecker K. et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.[Abstract/Free Full Text]
  • Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Cardiac Failure 1998;4:37-44.[Medline] [Order article via Infotrieve]
  • Brunner-La Rocca HP, Kaye DM,Woods RL, Hastings J., Esler MD Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-7.[Abstract/Free Full Text]
  • Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the Green Mamba (Dendroaspis angusticeps). J Biol Chem 1992;267:13928-32.[Abstract/Free Full Text]
  • Collins E., Bracamonte MP, Burnett JC, Jr., Miller VM Mechanism of relaxations to dendroaspis natriuretic peptide in canine coronary arteries. J Cardiovasc Pharmacol 2000;35: 614-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lang CC, Motwani JG, Coutie WJ, Struthers AD Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci 1992;82:619-23.[Web of Science][Medline] [Order article via Infotrieve]
  • Colucci WS, Elkayam U., Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.[Abstract/Free Full Text]
  • Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA 2002;287:1531-40.[Abstract/Free Full Text]
  • Burger AJ, Horton DP, LeJemtel T. et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Saito H., OgiharaT, Nakamaru M. et al. Hemodynamic, renal, and hormonal responses to alpha-human atrial natriuretic peptide in patients with congestive heart failure. Clin Pharmacol Ther 1987;42:142-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Munzel T., Kurz S., Holtz J. et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992;86:1089-98.[Abstract/Free Full Text]
  • Lisy O., Jougasaki M., Heublein D. et al. Renal actions of synthetic Dendroaspis natriuretic peptide. Kidney Int 1999;56:502-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1997;17(suppl 1): S37-S43.
  • Robl JA, Sun CQ, Stevenson J. et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997;40:1570-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wegner M., Hirth-Dietrich C., Stasch JP Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 1996;31:891-8.[Abstract/Free Full Text]
  • Wilkins MR, Settle SL, Stockmann PT, Needleman P. Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA 1990; 87:6465-9.[Abstract/Free Full Text]
  • Maki T., Nasa Y., Yamaguchi F. et al. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res 2001;51:608-17.[Abstract/Free Full Text]
  • Kimura M., Umemura K., Ohashi K., Nakashima M. Effect of ecadotril, a neutral endopeptidase inhibitor, on myocardial hypertrophy in the rat aortic insufficiency model. Can J Cardiol 1998;14:63-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Richards M., Espiner E., Frampton C. et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 1990;16:269-76.[Abstract/Free Full Text]
  • Margulies KB, Cavero PG, Seymour AA, Delaney NG, Burnett JC, Jr. Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor. Kidney Int 1990;38:67-72.[Web of Science][Medline] [Order article via Infotrieve]
  • Seymour AA, Fennell SA, Swerdel JN Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072. Hypertension 1989;14:87-97.[Abstract/Free Full Text]
  • Northridge DB, JardineA, Henderson E., Dilly SG, Dargie HJ Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function. Br Heart J 1992; 68:387-91.[Abstract/Free Full Text]
  • Lang CC, Motwani J., Coutie WJ, Struthers AD Influence of candoxatril on plasma brain natriuretic peptide in heart failure.[erratum appears in Lancet 1991;338:255.[CrossRef]
  • Good JM, Peters M., Wilkins M., Jackson N., Oakley CM, Cleland JG Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol 1995;25:1273-81.[Abstract]
  • Elsner D., Muntze A., Kromer EP, Riegger GA Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992;70:494-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Newby DE, McDonagh T., Currie PF, Northridge DB, Boon NA, Dargie HJ Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J 1998;19:1808-13.[Abstract/Free Full Text]
  • Northridge DB, Currie PF, Newby DE et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail 1999;1:67-72.[Abstract/Free Full Text]
  • Margulies KB, Barclay PL, Burnett JC, Jr.The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995;91:2036-42.[Abstract/Free Full Text]
  • Kohzuki M., Hodsman GP, Johnston CI Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol 1989;256:H533-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Knecht M., Pagel I., Langenickel T. et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 2002;71:2701-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • RayaTE, Lee RW,Westhoff T. et al. Captopril restores hemodynamic responsiveness to atrial natriuretic peptides in rats with heart failure. Circulation 1989;80:1886-92.[Abstract/Free Full Text]
  • Lee RW, Raya TE, Michael U. et al. Captopril and ANP: changes in renal hemodynamics, glomerularANP receptors and guanylate cyclase activity in rats with heart failure. J Pharmacol Exp Ther 1992;260:349.[Abstract/Free Full Text]
  • Campbell DJ, Anastopoulos F., Duncan AM, Jamed GM, Kladis A., Briscoe TA Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther 1998;287:567-77.[Abstract/Free Full Text]
  • Duncan AM, James GM,Anastasopoulos F., Kladis A., Briscoe TA, Campbell DJ Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J Pharmacol Exp Ther 1999;289:295-303.[Abstract/Free Full Text]
  • Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Combined neutral endopeptidase and angiotensin converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 1998;31(1):116-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gros C., Noel N., Souque A. et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-14.[Abstract/Free Full Text]
  • Corti R., Burnett JC, Jr., Rouleau JL, Ruschitzka F., Luscher TF Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104:1856-62.[Abstract/Free Full Text]
  • Trippodo NC, Fox M., Monticello TM, Panchal BC, Asaad MM Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999;34:782-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chen HH, Lainchbury JG, Matsuda Y., Harty GJ, Burnett JC, Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension 2001;38:187-91.[Abstract/Free Full Text]
  • Thomas CV, McDaniel GM, Holzgrefe HH et al. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol 1998;32:902-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Maki T., Nasa Y.,Tanonaka K.,Takahashi M.,Takeo S. Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation. J Pharmacol Exp Ther 2003;305:97-105.[Abstract/Free Full Text]
  • Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.[comment][erratum appears in Lancet 2000 Nov 18;356(9243):1774]. Lancet 2000;356:615-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Eisenstein EL, Nelson CL, Simon TA, SmittenAL, Lapuerta P., Mark DB Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. Am Heart J 2002;143:1112-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sheth T., Parker T., Block A. et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002;90:496-500.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Packer M., Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6.[Abstract/Free Full Text]
  • Coats AJ Omapatrilat-the story of Overture and Octave. Int J Cardiol 2002;86:1-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Regamey F., Maillard M., Nussberger J., Brunner HR, Burnier M. Renal haemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 2002;40:266-72.[Abstract/Free Full Text]
  • Lainchbury JG, Mark RA, Nicholls MG, Espiner EA, Yandle TG Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrinol Metab 1999;84:723-9.[Abstract/Free Full Text]
  • Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H., Nicholls MG Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-17.[Abstract/Free Full Text]
  • Chen HH, Lainchbury JG, Harty GJ, Burnett JC, Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002;105:999-1003.[Abstract/Free Full Text]
  • Pitt B., Zannad F., Remme WJ, Cody R., Castaigne A., Perez A., et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. (RALES) Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
  • Weber KT Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.[Free Full Text]
  • Bauersachs J., Fraccarollo D., Ertl G., Gretz N., Wehling M., Christ M. Striking increase of natriuresis by low dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 2000;102:2325-8.[Abstract/Free Full Text]
  • Jolobe OM Efficacy of low dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol 1993;19: 321-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nishida N., Ogawa T., Yamauchi T. et al. Treatment of cilazapril, an angiotensin converting enzyme inhibitor, changes the affinity of arginine receptor in the kidney of the spontaneousLy hypertensive rat. Res Commun Chem Pathol 1994;84:14352.
  • Farquharson CA, Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/ angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.[Abstract/Free Full Text]
  • Bauersachs J., Heck M., Fraccarollo D. et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. J Am Coll Cardiol 2002;39:351-8.[Abstract/Free Full Text]
  • EPHESUS Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
  • Krum H., Nolly H.,Workman D. et al.Efficacy of eplerenone added to renin angiotensin blockade in hypertensive patients. Hypertension 2000;40:117-23.[CrossRef]
  • Schafer A., Fraccarollo D., Hildemann SK, Tas P., Ertl G., Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: Effect on endothelial dysfunction. Cardiovasc Res 2003 (in press).
  • Lonn E., McKelvie R. Drug treatment in heart failure. BMJ 2000;320:1188-92.[Free Full Text]
  • Gottlieb SS, Skettino SL, Wolff A. et al. Effects of BG 9719 (CVT-124), an A1-adenosine receptor antagonist and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000; 35:56-9.[Abstract/Free Full Text]
  • Gottlieb SS, Brater DC, Thomas I. et al. BG 97119 (CVT-124), an A1-adenosine receptor antagonist protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-53.[Abstract/Free Full Text]
  • OhnishiA., OrituY., Okahara R. et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Palm C., Reimann D., Gross P. The role of vasopressin V2-antagonists in hyponatremia. Cardiovasc Res 2001;51:403-08.[Abstract/Free Full Text]
  • Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivapton, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 3, 140-148 (2003)
DOI: 10.3317/jraas.2003.022
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chee, K. H
Right arrow Articles by Lang, C. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chee, K. H
Right arrow Articles by Lang, C. C
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement